TREETOPP: A phase 2/3 study of varlitinib plus capecitabine versus placebo plus capecitabine as second-line treatment in patients with advanced or metastatic biliary tract cancers (BTCs).

Authors

Milind M. Javle

University of Texas MD Anderson Cancer Center, Houston, TX

Milind M. Javle , Do-Youn Oh , Masafumi Ikeda , Shukui Qin , Wei-Peng Yong , Yee Chao , Nicola McIntyre , Chih-Yi Hsieh , Lilian Chow , Alyssa Chang , Mark McHale , Bertil Lindmark

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2020 ASCO Virtual Scientific Program

bookmark_border

Results from TreeTopp: A randomized phase II study of the efficacy and safety of varlitinib plus capecitabine versus placebo in second-line (2L) advanced or metastatic biliary tract cancer (BTC).

First Author: Milind M. Javle

insert_chart_outlined

Poster

2019 Gastrointestinal Cancers Symposium

bookmark_border

A multicenter, phase Ib/2 study of varlitinib plus gemcitabine and cisplatin (gem/cis) for treatment of naïve, advanced, or metastatic biliary tract cancer (BTC).

First Author: Do-Youn Oh

insert_chart_outlined

Poster

2019 Gastrointestinal Cancers Symposium

bookmark_border

Efficacy and safety of varlitinib, a reversible pan-HER tyrosine kinase inhibitor, in combination with platinum-based regimens in biliary tract cancers: A pooled analysis from three phase I studies.

First Author: Aaron C. Tan

insert_chart_outlined

Poster

2021 Gastrointestinal Cancers Symposium

bookmark_border

Phase Ib trial of varlitinib plus weekly paclitaxel in EGFR/HER2 co-expressing advanced gastric cancer (AGC).

First Author: Yunbeom Sang